JPRN-jRCTs031190208招募中4 期
The effectiveness and the safety of AMNV in patient with herpes zoster treated with immunosuppressive agents:exploratory Study - SAPPHIRE study
Imafuku Shinichi0 个研究点目标入组 50 人开始时间: 2020年2月13日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients aged >= 20 years old who provide written informed consent to participation in the study.
- •(2) Patients who received immunosuppressive therapy (ex. Chemotherapy, oral steroid, cyclosporine, JAK inhibitor etc. ) for cancer (solid/ blood), transplantation or connective disease.
- •(3)Patients who appeared the rash within 5 days.
排除标准
- •(1) Patients has a known hypersensitivity to amenamevir.
- •(2) Patients have been treated with Rifampicin.
- •(3) Patients who are not expected to have an adequate response to oral antiviral medication.
- •(4) Patients have been treated antiviral drugs (except for anti-influenza drugs and ophthalmic agent) or immunoglobulins within 14 days prior to the obtainment of consent.
- •(5) Patients who cannot interrupt everolimus,cyclosporine,sirolimus,tacrolimus during the administration of amenamevir.
- •(6) Patients have been received treatment to Acquired Immune Deficiency Syndrome or Human Immunodeficiency Virus.
- •(7) Female patients who is breastfeeding, pregnant, or plans to become pregnant during the study.
- •(8) Other patients who are considered to be unsuitable for the study by the investigator or subinvestigator.
研究者
相似试验
进行中（未招募）
1 期
Comparison of effectiveness and safety of vaginally used Dequalinium Chloride with orally taken Metronidazole in the treatment of bacterial vaginosisBacterial vaginosisEUCTR2020-002489-15-SKMedinova AG236
进行中（未招募）
不适用
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - Macular Edema Incidence/Severity Reduction with NEVANACCystoid Macular EdemaEUCTR2009-010536-17-ITAlcon Research LTD260
进行中（未招募）
不适用
A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - Macular Edema Incidence/Severity Reduction with NEVANAC®EUCTR2009-010536-17-DKALCON RESEARCH, LTD.260
进行中（未招募）
不适用
A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - Macular Edema Incidence/Severity Reduction with NEVANAC®EUCTR2009-010536-17-DEALCON RESEARCH, LTD.260
已完成
3 期
A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy PatientsA Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients10010463NL-OMON35481Alcon Laboratories30